The short answer
Vascular effects are among the most consistently reported findings, with Seiwerth and colleagues reviewing BPC-157 and blood vessels in Current Pharmaceutical Design in 2014. Angiogenesis is the most plausible common thread linking reported activity across otherwise unrelated tissues.
Key facts
- Key review
- Seiwerth, Curr Pharm Des 2014 (PMID 23782145)
- Reported involvement
- VEGF-related signalling
- Model systems
- Predominantly rat
- Why it matters
- Repair in most tissues requires vasculature
- Receptor
- None identified
- Human data
- Limited
Why angiogenesis could be the unifying thread
BPC-157 is reported active in gut, tendon, ligament, muscle and eye. Those tissues have little in common except that repair in all of them requires blood supply. If a compound affects vessel formation, effects across unrelated tissues become less surprising: one mechanism producing many apparent activities rather than many separate mechanisms.
What the literature reports
Seiwerth and colleagues reviewed the vascular findings in 2014. Reported involvement includes VEGF-related signalling, which is the principal pathway driving new vessel formation. Effects on vessel behaviour in injury models recur across the Zagreb group's output in different tissue systems.
Research material referenced
BPC-157 5mg, third-party HPLC tested
The mechanistic gap that remains
Reporting that a compound affects angiogenesis is not the same as explaining how. Without an identified receptor there is no molecular starting point, so the angiogenic finding is itself a description rather than a mechanism. It moves the question from why does this work in five tissues to how does it affect vessels, which is progress but not resolution.
The caution angiogenesis always warrants
Promoting vessel growth is not uniformly beneficial. Angiogenesis is central to tumour growth as well as to tissue repair, which is why the therapeutic angiogenesis field has proceeded carefully. A compound reported to promote it deserves that same care in description, and this library reports findings rather than characterising them as benefits.
Where the evidence sits
Predominantly rat models from one research group. The currently recruiting Phase 2 trial in hamstring muscle strain is relevant here. Muscle repair depends on vascular supply, so a positive result would be consistent with the angiogenic hypothesis, though a clinical endpoint does not identify a mechanism.
Frequently asked questions
Does BPC-157 promote angiogenesis?
Vascular effects are consistently reported in preclinical models, with VEGF-related signalling implicated. The mechanism behind it is not established.
Why would that explain effects in different tissues?
Repair in most tissues depends on blood supply, so one vascular mechanism could produce apparent activity across unrelated systems.
Is promoting angiogenesis desirable?
Not uniformly. It underlies tumour growth as well as tissue repair, which is why the field describes it carefully.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov: BPC 157 Phase 2 (NCT07437547)clinicaltrials.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- Tendon and Ligament ModelsKrivic on Achilles detachment and Cerovecki on ligament healing, both in the Journal of Orthopaedic Research. What rat models can and cannot establish.
- Growth Factor Signalling in the BPC-157 LiteratureReported interactions with growth-factor systems are part of the multi-pathway description. What that means when no receptor for the peptide is known.
- BPC-157 Studied Effects, Sorted by EvidenceGastrointestinal, tendon, ligament and vascular models, plus clinical development as PL-14736 and a Phase 2 recruiting now. Ranked by how well established.
- BPC-157 Side Effects and the Absence of Human DataNo controlled human safety study exists. What the rodent literature reports, the theoretical concern that follows from its own mechanism, and what nobody knows.
- What BPC-157 Is Claimed to Do, and in Which SpeciesTendon, ligament, gut and vascular findings - almost entirely in rats. What has been demonstrated, in which species, and why no human timeline exists.